joint Meeting Timetable
| Thursday, October 5, 2023 | |
| Hall A | |
| Hematology (IACH) |
|
| 09:00-09:30 | Welcome Coffee |
| 09:30-12:30 | Cutting Edge Cases and Controversies: A Workshop in Transplant Excellence Industry-supported Workshop by Jazz Pharmaceuticals, On-Site only |
| 12:30-13:00 | Lunch Pick-up and Break |
| 13:00-14:30 | IACH Lunch Session: Chronic GVHD: from biology to therapy |
| 14:30-14:45 | Technical Break |
| 14:45-16:25 | IACH Session: Advances in hematology (Part 1) |
| 16:25-16:45 | Coffee Break |
| 16:45-18:30 | IACH Session: Advances in hematology (Part 2) |
| 18:30-19:30 | Opening Lectures and Awards Session |
| 19:30 | Meeting Welcome Reception |
| Friday, October 6, 2023 | |||
| Hall A |
Hall B |
Hall C |
|
| MDS-AML-ALL (COMydAL) |
Lymphoma (COLYM) |
Myeloproliferative Neoplasms (MPNCo&D) |
|
| 07:45-08:00 | Welcome Coffee | ||
| 08:00-09:00 | Shifting the treatment paradigm in myelofibrosis: What to expect from combination therapies Industry-supported Morning Symposium by Menarini Stemline |
||
| 09:00-09:15 | Technical Break | ||
| 09:15-10:45 | Session 1: Classification, risk stratification & response assessment updates for MDS |
Session 1: What’s new in the field of lymphomas? Keynote lectures |
Session 1: Polycythemia Vera in 2023 and beyond |
| 10:45-11:15 | Coffee Break | ||
| 11:15-12:45 | Session 2: Management of lower risk MDS |
Session 2: CLL and Richter’s syndrome |
Session 2: Essential thrombocytosis – Can we do better? |
| 12:45-13:15 | Lunch Pick-up and Break | ||
| 13:15-14:30 | IACH Lunch Session: State-of-the-art in the management of … |
Raising the Bar in Cytopenic Myelofibrosis Industry-supported Lunch Symposium by GSK (starting at 13:00) |
|
| 14:30-14:45 | Technical Break | ||
| 14:45-16:15 | Session 3: Management of higher risk MDS |
Session 3: Follicular lymphoma |
Session 3: Myelofibrosis: current and novel approaches in a rapidly developing field |
| 16:15-16:30 | Coffee Break | ||
| 16:30-18:00 | Session 4: Prognosis, MRD and transplantation for AML |
Session 4: Diffuse large B cell lymphomas |
Session 4: Treatment of high-risk MF |
| Saturday, October 7, 2023 | |||
| Hall A |
Hall B |
Hall C |
|
| MDS-AML-ALL (COMydAL) |
Lymphoma (COLYM) |
Myeloproliferative Neoplasms (MPNCo&D) |
|
| 08:30-09:00 | Welcome Coffee | ||
| 09:00-10:30 | Session 5: Updates in AML management in 2023 – Agents in clinic |
Session 5: Peripheral T cell lymphomas |
Session 5: AYA MPNs: pregnancy thromboses and special considerations (ending 10:45) |
| 10:30-11:00 | Coffee Break | ||
| 11:00-12:30 | Session 6: Updates in AML management in 2023 – Investigational approaches |
Session 6: Hodgkin lymphoma |
Session 6: Rare MPNs – Focus on emerging subtypes |
| 12:30-13:00 | Lunch Pick-up and Break | ||
| 13:00-14:30 | The future of AML treatment: As easy as 123? Industry-supported Lunch Symposium by Menarini Stemline |
IACH Meet the Experts Session |
|
| 14:30-14:45 | Technical Break | ||
| 14:45-16:15 | Session 7: How do I manage ALL in 2023? |
COLYM Plenary Lecture (14:45-15:15) |
Session 7: Current and future considerations in MPNs and rare hematologic malignancies: building innovative, sustainable programs across the world |
| Session 7: Mantle cell lymphoma (15:15-16:15) |
|||
| 16:15-16:30 | Coffee Break | ||
| 16:30-17:00 | IACH Closing Plenary Lecture |
||